G
Gemma G. Kenter
Researcher at Netherlands Cancer Institute
Publications - 202
Citations - 15694
Gemma G. Kenter is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Cervical cancer & Cancer. The author has an hindex of 60, co-authored 194 publications receiving 13775 citations. Previous affiliations of Gemma G. Kenter include VU University Amsterdam & Leiden University.
Papers
More filters
Journal ArticleDOI
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote,Claes G. Tropé,Frédéric Amant,G.B. Kristensen,Tom Ehlen,N Johnson,René H.M. Verheijen,Maria E. L. van der Burg,A. J. Lacave,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Corneel Coens,Leen Verleye,Gavin Stuart,Sergio Pecorelli,Nicholas Reed +17 more
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Journal ArticleDOI
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Gemma G. Kenter,Marij J. P. Welters,A. Rob P. M. Valentijn,Margriet J. G. Löwik,Dorien M A Berends-van der Meer,Annelies P G Vloon,Farah Essahsah,Lorraine M. Fathers,Rienk Offringa,Jan W. Drijfhout,Amon R. Wafelman,Jaap Oostendorp,Gert Jan Fleuren,Sjoerd H. van der Burg,Cornelis J. M. Melief +14 more
TL;DR: Clinical responses in women with HPV- 16-positive, grade 3 vulvar intraepithelial neoplasia can be achieved by vaccination with a synthetic long-peptide vaccine against the HPV-16 oncoproteins E6 and E7.
Journal ArticleDOI
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial
D.C. Rijkaart,Johannes Berkhof,Lawrence Rozendaal,Folkert J. van Kemenade,N. W. J. Bulkmans,Daniëlle A M Heideman,Gemma G. Kenter,Jack Cuzick,Peter J.F. Snijders,Chris J.L.M. Meijer +9 more
TL;DR: The aim of this study was to assess whether HPV DNA testing in the first screen decreases detection of cervical intraepithelial neoplasia (CIN) grade 3 or worse, CIN grade 2 or better, and cervical cancer in the second screening.
Journal ArticleDOI
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.
Yvonne M.C. Hendriks,Anja Wagner,Hans Morreau,Fred H. Menko,Astrid Stormorken,Franz Quehenberger,Lodewijk A. Sandkuijl,Pål Møller,Maurizio Genuardi,Hans C. van Houwelingen,Carli M. J. Tops,Marjo van Puijenbroek,Paul Verkuijlen,Gemma G. Kenter,Anneke M. van Mil,Hanne Meijers-Heijboer,Gita B Tan,Martijn H. Breuning,Riccardo Fodde,Juul T. Wijnen,A H J T Bröcker-Vriends,Hans F. A. Vasen +21 more
TL;DR: The aim of this study was to determine the cumulative risk of developing cancer in a large series of MSH6 mutation carriers, and recommended starting colonoscopic surveillance in female MSH 6 mutation carriers from age 30 years.
Journal ArticleDOI
High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer
Sytse J. Piersma,Ekaterina S. Jordanova,Mariëtte I.E. van Poelgeest,Kitty M. C. Kwappenberg,Jeanette M. van der Hulst,Jan W. Drijfhout,Cornelis J. M. Melief,Gemma G. Kenter,Gert Jan Fleuren,Rienk Offringa,Sjoerd H. van der Burg +10 more
TL;DR: The data indicate that, especially in a sub group of LN- patients, a strong and effective interaction between immune system and tumor exists, and this subgroup of cervical cancer patients may have the best prognosis.